Legal Opinion
Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA, Inc.
District Court, D. Delaware
Decided November 16, 2016No. Civ. No. 14-874-SLRPublishedCited by 2 opinions
1Opinion of the Court
OPINION
Robinson, District Judge
I. INTRODUCTION
This action arises out of the filing of Abbreviated New Drug Application (“ANDA”) No. 205149 by defendant Teva *785Pharmaceuticals USA, Inc. (“Teva”) seeking to produce and market a generic mometasone furoate nasal spray. (D.I. 123) On July 3, 2014, plaintiff Merck Sharp & Dohme Corp. (“Merck”) brought this action alleging infringement of U.S. Patent No. 6,127,353 (“the ’353 patent”).1 (D.I. 1) Merck filed an amended complaint on August 17, 2015, which Teva answered on August 31, 2015. (D.I. 123; D.I. 130) The court held a Markman hearing on July 31,…
2Cases cited24 opinions
- MARKMAN Et Al. v. WESTVIEW INSTRUMENTS, INC., Et Al.Supreme Court of the United States · 1996
- Herbert Markman and Positek, Inc. v. Westview Instruments, Inc. And Althon Enterprises, Inc.Court of Appeals for the Federal Circuit · 1995
- Teva Pharm. United States, Inc. v. Sandoz, Inc.Supreme Court of the United States · 2015
- Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co.Court of Appeals for the Federal Circuit · 2010
- Exergen Corp. v. Wal-Mart Stores, Inc.Court of Appeals for the Federal Circuit · 2009
19 more not listed; retrieve them via the Exa API.
3Cited by2 opinions
- Novartis Pharmaceuticals Corp. v. Breckenridge Pharmaceutical, Inc.District Court, D. Delaware · 2017
- Fairhaven Health LLC v. BioOrigyn LLCDistrict Court, W.D. Washington · 2023